The Prevalence of Hypogonadism and the Effectiveness of Androgen Administration on Body Composition in HIV-Infected Men: A Meta-Analysis

Daniele Santi 1,2*, Giorgia Spaggiari 2, Walter Vena 3, Alessandro Pizzocaro 3, Mario Maggi 4, Vincenzo Rochira 1,2,*, and Giovanni Corona 5

Abstract: Background: Hypogonadism is a common comorbidity in human immunodeficiency virus (HIV)-infected men, although the real prevalence is difficult to be estimated. Moreover, in HIV settings, the efficacy of exogenous testosterone (Te) administration at improving body composition remains unclear. Aim of the study: This review has a double aim. First, to estimate the prevalence of pituitary–testis axis abnormality in HIV-infected patients compared to uninfected subjects. Second, to evaluate the effect of androgen administration on body composition in HIV-infected men. Materials and Methods: A systematic review of the literature and meta-analysis was carried out. Two separated literature searches were performed, the first to evaluate the prevalence of Te deficiency in HIV-infected men and the second one to evaluate effects of androgen administration on body composition. Results: The overall prevalence of Te deficiency in HIV-infected men was calculated from 41 studies, showing a 26% prevalence, which was even higher when free T (fT) levels, more than total T, were considered. Indeed, TT serum levels were similar between HIV patients and controls, although higher SHBG and lower fT were detected in HIV populations. When HIV-infected men were treated with exogenous Te, a significant increase in body weight, lean body mass and fat free mass was detected. Conclusion: The systematic review confirms the high prevalence of Te deficiency in HIV-infected men was calculated from 41 studies, showing a 26% prevalence, which was even higher when free T (fT) levels, more than total T, were considered. Indeed, TT serum levels were similar between HIV patients and controls, although higher SHBG and lower fT were detected in HIV populations. When HIV-infected men were treated with exogenous Te, a significant increase in body weight, lean body mass and fat free mass was detected. Conclusion: The systematic review confirms the high prevalence of Te deficiency in HIV-infected men, particularly when fT has been considered. Moreover, chronic androgen supplementation improves body composition, affecting the lean mass compartment. However, considering the general frailty of HIV patients, a tailored indication for Te therapy should be advocated.

Keywords: testosterone; HIV; body composition; androgen replacement treatment; hypogonadism

1. Introduction

Since the early 1990s, the advent of highly active antiretroviral therapy (HAART) drastically changed the natural history of human immunodeficiency virus (HIV) infection, moving from a quickly fatal illness to a chronic disease [1]. Thus, although the initial therapeutic goal of HIV-infection management was patients’ survival, in the post-HAART era, the endpoint of both therapeutic approaches and research studies shifted to metabolic comorbidities and progressive population aging [2]. Among several chronic non-infectious comorbidities observed in HIV-infected patients together with increased life expectancy, the endocrine system is not spared from HIV infection [3]. Indeed, an impairment of
the hypothalamic–pituitary–gonadal axis is frequently reported in HIV populations, although there is a highly variable incidence, depending on both the criteria used to diagnose hypogonadism and the clinical characteristics of patients enrolled [3]. Despite this heterogeneous picture, the well-known age-related decline in testosterone (Te) serum levels seems anticipated in HIV patients [4,5]. This progressive decline could be due either to a direct viral action on glandular tissue, or to the HAART-related sequelae, although the exact pathogenic mechanism remains to be elucidated [4,5]. Moreover, available studies assessing the prevalence of hypogonadism in HIV-infected patients reported very variable percentages, leaving open the question of the real interconnection between hypogonadism and HIV [3].

The relevance of hypogonadism in HIV settings has progressively increased in recent years, since it has been suggested as a marker of poor health status and frailty in the general population [6,7] and in HIV subjects [5,8]. Te and each related derivative compound (such as anabolic-androgenic steroids) [9] are used and, in terms of androgen anabolic properties, an involvement of Te reduction in HIV-related changes in body composition has been investigated [10]. Indeed, a variable degree of body composition alterations is described in HIV populations, such as subcutaneous lipodystrophy, increased amounts of visceral adipose tissue and wasting syndrome (WS), defined as an involuntary 10% weight loss in one year or a 5% weight loss in six months [11]. In general, HIV-related body composition changes and WS mainly concern the lean mass compartment, without an evident modification in total body weight [12]. This reduction could be measured by assessing the total amount of non-fat portions of the body, i.e., the lean body mass (LBM) (including a minimal quota of essential fat), the fat-free mass (FFM) (in which the essential fat is absent), and/or the body mass cell (BMC) (identifying all the metabolically active tissues of the body) [13]. The WS prevalence in HIV-infected patients is estimated at around 20% in the post-HAART period. Therefore, WS remains a relevant medical problem, considering its strict correlation with several metabolic comorbidities, reduced global performance status and impaired survival [12,14–18]. Since Te and/or Te-derived analogues are steroid molecules that are largely known to promote muscle mass gain [9,19,20], it is not surprising that exogenous androgenic treatment constituted an attractive therapeutic option for preventing WS in HIV populations. Hence, for many years, androgen treatments have been proposed in HIV settings, even in the absence of biochemical hypogonadism, for the contrasting of several disease-associated conditions, such as muscle mass lost, reduced bone mineral density, impaired mood and poor quality of life [21–26]. In 2005, a Cochrane meta-analysis evaluated the anabolic steroids efficacy on HIV-related WS, documenting a minimal increase in both LBM and body weight, despite several limitations due to the low number of included studies, the brief mean treatment duration and the heterogeneity of the subjects enrolled [20]. Similar results were thereafter reported by Corona et al. [27] in a further meta-analysis. However, other clinical trials were published over the years on this topic and no recent systematic literature review is still available regarding the effects of androgen administration on body composition in HIV-infected patients.

Considering the available evidence, this systematic review and meta-analysis was designed with a double aim: i) to better estimate the prevalence of hypogonadism in HIV subjects and the pituitary–testis hormonal profile in HIV patients in comparison to control men and ii) to comprehensively evaluate the effectiveness of Te and other androgenic compounds on body composition in HIV men.

2. Materials and Methods

We performed a meta-analysis according to the Cochrane Collaboration and PRISMA statement (Supplementary File 1). To ensure originality and transparency of the review process, the meta-analysis was registered in the International Prospective Register of Systematic Reviews (PROSPERO; registration ID: CRD42018093170).

Two separate literature searches were performed. The first literature search was conducted to evaluate the prevalence of hypogonadism in HIV patients and to compare
the pituitary–testis hormonal abnormalities between HIV-infected men and controls. The search was conducted until April 2021 for English-language articles published in the MEDLINE and Embase databases, using the following criteria: ((((Testosterone) OR Androgen) AND HIV) OR Human Immunodeficiency virus) OR HIV man) OR HIV men) OR HIV infected men. The second literature search was performed to evaluate the effects of androgen administration on body composition in HIV-infected patients, using the following criteria: (((((((Testosterone) OR Testosterone administration) OR Testosterone therapy) OR Testosterone treatment) OR Androgen) OR Androgen administration) AND HIV) OR Human Immunodeficiency virus) OR HIV man) OR HIV men) OR HIV infected men.

2.1. Study Selection and Inclusion Criteria

2.1.1. Literature Search 1

To identify the incidence of hypogonadism in HIV populations, the first literature search evaluated all clinical studies in which total Te (TT) serum levels were evaluated in HIV-infected men. In this first selection, both interventional and observational studies, either prospective or retrospective, were searched and collected, without specific inclusion or exclusion criteria for the study design. Randomization and presence of controls were not considered as inclusion criteria. Once longitudinal studies were considered, the enrolment visit was evaluated for data extraction.

Since the diagnosis of hypogonadism could be performed using different cut-offs [28, 29], we selected those studies in which TT serum levels were reported, alongside the eventual percentage of hypogonadal patients calculated by authors. Thus, the inclusion criteria were: (i) HIV infection, (ii) male sex, and (iii) available TT serum levels. When both males and females were enrolled, the study was considered only if it was possible to discriminate hormonal data between the two genders.

2.1.2. Literature Search 2

In order to evaluate the effects of androgen administration on body composition in HIV-infected men, the second literature search considered all randomized controlled clinical trials in which any kind of androgenic treatment was administered to HIV male patients. In particular, the inclusion criteria were: (i) HIV infection, (ii) male sex, (iii) randomized clinical trial, (iv) androgen administration, and (v) control group. All molecules with androgenic action were eligible and the analysis was performed separating Te and androgens-related molecules, such as nandrolone (N), oxandrolone and dehydroepiandrosterone (DHEA). Only studies evaluating the efficacy of androgen administration on body composition were included. Body composition was evaluated considering all possible parameters reported in each trial and only those parameters reported in at least three studies were meta-analysed. Each parameter was considered as the mean change after treatment in the study and control groups.

2.2. Data Collection Process and Quality

For both literature searches, three authors (DS, GS and WV) separately performed the selection, collecting abstracts of each study. All abstracts were evaluated for inclusion criteria and data were extracted from each study that was considered eligible, with regard to the study design, year of publication, number of included/excluded subjects and inclusion/exclusion criteria. AP, DS, GS, GC, MM, VR and WV performed quality control checks on the extracted data.

For the first literature search, the primary endpoint was TT serum levels in HIV-infected men. Secondary endpoints were: (i) prevalence of hypogonadism, (ii) Te cut-offs used to diagnose hypogonadism, (iii) fT serum levels, and (iv) sex hormone binding globulin (SHBG) serum levels.

For the second literature search, the primary endpoint was the body composition evaluation after androgen administration. Comparisons between HIV androgen-treated and HIV untreated men as well as between HIV androgens-treated subjects and healthy
untreated controls were evaluated. Secondary endpoints were (i) T_e serum levels and (ii) safety of androgen treatment, considering drop-out rates.

The risk of bias was assessed independently by three investigators (DS, GS and WV), using the Cochrane risk-of-bias algorithm. For each trial included in the comprehensive evaluation, several quality criteria and methodological details were considered. They included: (i) method of randomization, (ii) concealment of allocation, (iii) presence or absence of blinding to treatment allocation, (iv) duration and type of treatment and follow-up phases, (v) number of participants recruited, analysed or lost during the follow-up, (vi) timing of trial, (vii) whether an intention to treat analysis was noted, (viii) whether a power calculation was performed, (ix) source of funding, and (x) criteria for including participants and assessing outcomes.

2.3. Data Synthesis and Analysis

Using the Review Manager (RevMan) 5.3 software (Version 5.3.1, Copenhagen, Denmark, 2014), continuous variables were comprehensively evaluated as inverse variance of mean variables. Dichotomous variables were comprehensively evaluated using the Mantel–Haenszel method. Heterogeneity in mortality rate was assessed using $I^2$ statistics. Even when a low heterogeneity was detected, a random-effects model was applied, because the validity of tests of heterogeneity can be limited with a small number of component studies. Funnel plots and the Begg-adjusted rank correlation test was used to estimate possible publication or disclosure bias. Sensitivity analyses were performed, considering studies in which androgens were administered and considering the presence at baseline of either hypogonadism or WS. In addition, a meta-regression analysis was performed to test the effect of different parameters on the prevalence of hypogonadism in HIV patients. Weighted mean differences and 95% CIs were estimated for the literature search. Values of $p < 0.05$ were considered statistically significant.

3. Results

3.1. Literature Search 1

In the first literature search, 15,631 papers were identified and 69 studies were selected for full text evaluation, since they fulfilled the inclusion criteria (Figure 1). Forty-six studies were included in qualitative and quantitative analyses. Among these studies, 30 were cohort and 16 case-control studies. The residual 23 studies were excluded after the full-text evaluation for unavailability of T_e serum levels or because they were abstracts presented during congresses (Figure 1). Finally, 46 studies were evaluated and reported, and 41 studies were included in the analysis (Table 1 and Supplementary Table S1). In particular, 39 studies provided information on the prevalence hypogonadism, and 13 on T_T levels, whereas data on SHBG and fT were available in five and six studies, respectively. The retrieved studies included 9,466 and 654 HIV subjects under HAART treatment and controls, respectively. The mean age and body mass index (BMI) were 42.4 ± 6.2 years and 23.7 ± 1.9 kg/m², respectively.
Table 1. Characteristics of studies detected with the first literature search.

| Author Name | Year | Study Design | Definition of Hypogonadism | Control Group | Control Group Criteria | HIV Patients (n) | HIV Patients Age (Years) | Controls (n) | Controls Age (Years) |
|-------------|------|--------------|----------------------------|---------------|------------------------|-----------------|--------------------------|--------------|----------------------|
| Dobs        | 1988 | One-arm, Longitudinal | NA                         | No            | NA                     | 19              | 35 ± 13.1                | 0            | 36.8 ± 5.5           |
| Croxson     | 1989 | Longitudinal   | TT < 19 nmol/L             | Healthy       | Healthy homosexual     | 32              | 32.9 ± 4.7               | 26           | 32.9 ± 4.7           |
| Raffi F     | 1991 | Cross-sectional | TT < 10.4 nmol/L           | NA            | NA                     | 67              |                         |              |                      |
| Laudat      | 1995 | Cross-sectional | NA                         | Yes           | Healthy                | 58              | 36.1 ± 8.6               | 11           | 36.8 ± 5.5           |
| Grinspoon   | 1996 | Cross-sectional | fT < 41.6 pmol/L           | NA            | NA                     | 77              | 39 ± 7                   | 28           | 32 ± 7               |
| Dobs        | 1996 | Cross-Sectional | NA                         | No            | NA                     | 13              | 45 ± 7.2                 | 13           | 44 ± 6.4             |
| Bhasin      | 1998 | RCT           | NA                         | No            | NA                     | 32              |                         |              |                      |
| Salehian    | 1999 | Longitudinal   | TT < 12.14 nmol/L          | Yes           | Healthy                | 56              | 34 ± 6                   | 28           | 32 ± 7               |
| Arver       | 1999 | Longitudinal   | TT < 9.5 nmol/L            | Yes           | Healthy                | 148             | 40 ± 1                   | 42           | 31 ± 2               |
| Kopicko     | 1999 | Cross-sectional | TT < 13.9 nmol/L          | No            | NA                     | 587             | 38.3 ± 8                 |              |                      |
| Dobs        | 1999 | RCT           | TT < 13.9 nmol/L           | No            | NA                     | 123             | 40 ± 7.5                 |              |                      |
| Retschel    | 2000 | Cross-Sectional | NA                         | Yes           | Healthy                | 90              | 39 ± 1                   | 22           | 38 ± 1               |
| Hadigan     | 2000 | RCT           | NA                         | Yes           | Healthy                | 50              | 38.9 ± 6.4               | 20           | 35.2 ± 6.3           |
| Grinspoon   | 2000 | RCT           | fT < 41.6 pmol/L           | No            | NA                     | 61              | 41.4 ± 2                 |              |                      |
| Rabkin      | 2000 | RCT           | TT < 10.4 nmol/L           | No            | NA                     | 70              | 39.1 ± 8.1               |              |                      |
| Biglia      | 2004 | case-control  | NA                         | No            | NA                     | 84              | 43.5 ± 10.5              |              |                      |
| Crum-Cianflone | 2007 | Cross-Sectional | TT < 10.4 nmol/L          | No            | NA                     | 300             | 39.4 ± 9.2               |              |                      |
| Andersen    | 2007 | Cross-Sectional | NA                         | No            | NA                     | 16              | 50 ± 8                   |              |                      |
| Mulligan    | 2007 | RCT           | NA                         | No            | NA                     | 79              | 40.1 ± 10.6              |              |                      |
| Knapp       | 2008 | open-label switch study | TT < 10.4 nmol/L          | No            | NA                     | 61              | 43.2 ± 6.7               |              |                      |
| Teichmann   | 2009 | Cross-sectional | TT < 10.4 nmol/L          | Yes           | Healthy                | 80              | 37.1 ± 5.7               | 20           | 35.4 ± 4.1           |
| Moreno-Pérez | 2010 | Cross-sectional | fT < 220 pmol/L           | No            | NA                     | 90              | 42 ± 8.2                 |              |                      |
| Rochira     | 2011 | Cross-sectional | TT < 10.4 nmol/L          | No            | NA                     | 1325            | 44.74                   |              |                      |
| Pepe        | 2012 | Cross-sectional | fT < 225 pmol/L           | Yes           | Healthy                | 50              | 48.6 ± 9.4               | 27           | 49.1 ± 8.3           |
| Zona S      | 2012 | Cross-sectional | TT <10.4 nmol/L           | Yes           | Healthy                | 441             | 44.8 ± 5.9               | 71           | 36.7 ± 11.9          |
Table 1. Cont.

| Author Name | Year   | Study Design | Definition of Hypogonadism | Control Group Criteria | Control Group | HIV Patients (n) | HIV Patients Age (Years) | Controls (n) | Controls Age (Years) |
|-------------|--------|--------------|----------------------------|------------------------|---------------|------------------|--------------------------|--------------|-----------------------|
| Sunchatawirul | 2012   | Cross-sectional | fT < 225 pmol/L | No | NA | 491 | 37.1 ± 1.7 | |
| Guaraldi    | 2012   | Cross-sectional | TT < 10.4 nmol/L | No | NA | 133 | 48.8 ± 7.4 | |
| De Ryck     | 2013   | Cross-sectional | fT < 220 pmol/L | No | NA | 49 | 48.7 ± 2.9 | |
| Pérez       | 2013   | Cross-sectional | TT < 10.4 nmol/L | No | NA | 158 | 45.8 ± 4.1 | |
| Pepe        | 2014   | Cross-sectional | fT < 225 pmol/L | No | NA | 41 | 48.3 ± 8.3 | |
| Rochira     | 2015   | Cross-sectional | TT < 10.4 nmol/L | No | NA | 1359 | 45 ± 1.2 | |
| Bhata       | 2015   | Cross-sectional | NA | No | NA | 992 | 44 ± 2 | |
| Pathak      | 2015   | Longitudinal  | NA | No | NA | 45 | 36.8 ± 8.8 | |
| Gomes       | 2016   | Cross-sectional | TT < 9.7 nmol/L or fT < 83.7 pmol/L | No | NA | 245 | 48 ± 11.2 | |
| Santi       | 2016   | Cross-sectional | TT < 10.4 nmol/L | No | NA | 1204 | 45.6 ± 7.3 | |
| Bajaj       | 2017   | Cross-sectional | TT < 10.4 nmol/L | Yes | Healthy | 81 | 82 | |
| Dutta       | 2017   | Cross-sectional | TT < 10.4 nmol/L | No | NA | 225 | 39.5 ± 41 | |
| Price       | 2019   | Cross-sectional | NA | Yes | Healthy | 340 | 52.0 ± 1.5 | 190 | 54.1 ± 2.2 |
| Bajaj       | 2020   | Cross-sectional | TT < 8.36 nmol/L | No | NA | 84 | 42.3 ± 10.5 | |
| Pezzaioli   | 2020   | Cross-sectional | TT < 12 nmol/L or fT < 83.7 pmol/L | No | NA | 94 | 53.1 ± 1.8 | |
| Postel      | 2021   | Cross-sectional | fT < 225 pmol/L | Yes | Healthy | 205 | 61.5 ± 7.2 | 117 | 62 ± 8.1 |
| de Vincentis| 2021   | Cross-sectional | TT < 10.4 nmol/L | no | NA | 316 | 45.3 ± 5.3 | |
| Quiros-Roldan | 2021  | Cross-sectional | TT < 12 nmol/L or fT < 83.7 pmol/L | No | NA | 107 | 53.9 ± 2.0 | |
| Pilatz      | 2021   | Longitudinal  | TT < 8 nmol/L | No | NA | 87 | 43.1 ± 2.2 | |

fT: free testosterone; HIV: human immunodeficiency virus; NA: not available; RCT: randomized clinical trial; TT: total testosterone.

3.2. Hypogonadism Prevalence

The $I^2$ value for the hypogonadism rate was 93.9, $p < 0.0001$. The funnel plot and Begg-adjusted rank correlation test suggested no major publication bias (Kendall’s $\tau$: −0.03; $p = 0.80$). Overall, the prevalence of hypogonadism in HIV subjects was 26% [22,30] (Figure 2 and Supplementary Figure S1, Panel A). The latter was significantly higher when fT was considered, as compared to TT (33% versus 19% $p < 0.001$). Those studies that used, as a cut-off for T-deficiency, a TT value above 12 nmol/L were excluded from the analysis (Q = 8.93; $p < 0.001$, see also Figure 2 and Supplementary Figure S1, Panel B), since they did not satisfy the criteria for the definition of hypogonadism [30]. Interestingly, when the whole population was considered, the prevalence of hypogonadism was inversely correlated with CD4+ cell count and year of publication (Supplementary Figure S2, Panel A and B). Conversely, no association between hypogonadism rate and age, BMI or TT levels at enrolment was observed (not shown).
3.3. Hormonal profile

The $I^2$ value for TT concentration was 92.3, $p < 0.0001$. The funnel plot and Begg-adjusted rank correlation test suggested no major publication bias (Kendall’s $\tau$: 0.14; $p = 0.54$). No significant difference for TT serum levels was observed between HIV patients and controls (Figure 3, Panel A). However, subjects with HIV showed significantly higher SHBG levels when compared to controls (Figure 3, Panel B). Accordingly, lower levels of $fT$ were observed in HIV patients when compared to controls (Figure 3, Panel C). Data on gonadotropin levels were available in five studies (Table 1). No significant differences between cases and controls for FSH levels were observed (Figure 3, Panel D), whereas a trend toward higher LH levels in HIV subjects was observed ($p = 0.07$, Figure 3, Panel E).

Panel A

Figure 3. Cont.
3.4. Literature Search 2

The second literature search identified 23,636 papers, and 33 studies were included in the full-text analysis, since they fulfilled the inclusion criteria (Figure 1). After the full-text evaluation, 17 studies were finally considered (Figure 1 and Table 2). Among the 12 trials excluded during the full text evaluation, four trials did not contemplate a control group, four trials did not report body composition parameters, seven trials considered male and female patients together and one provided a previous Te administration in both groups before androgen supplementation (Table S2) (Figure 1).

Figure 3. Forest plot comparing HIV-infected patients and controls detected in the first literature search for total testosterone serum levels (panel A), sex hormone binding globulin (SHBG) (panel B), free testosterone (Panel C), follicle stimulating hormone (FSH) (panel D), and luteinising hormone (LH) (panel E).
Finally, 1267 HAART-treated HIV-infected men were considered in the analysis, 661 treated with androgens and 606 with placebo. Two sensitivity analyses were performed considering patients’ baseline characteristics. First, papers evaluating the use of Te were divided according to the presence of hypogonadism (eight studies) considering the cut off of 12.1 nmol/L [31–38] or the absence of hypogonadism (eight studies) [10,21,25,39–43] as an inclusion criterion. Second, papers evaluating the use of Te were divided according to the presence (13 studies) [10,21,32–36,39–43] or absence (four studies) [25,31,37,38] of WS as an inclusion criterion.

Table 2. Characteristics of studies included in the meta-analysis (search 2).
Table 2. Cont.

| Author    | Year | Androgen Molecule(s) | Androgen Dosages | Treatment Duration | Endpoints                        | Study Group—Type of Patients | Control Group—Type of Patients |
|-----------|------|----------------------|------------------|--------------------|----------------------------------|------------------------------|--------------------------------|
| Grinspoon S | 2000 | Testosterone         | 200 mg weekly    | 12 weeks           | Body composition                 | HIV-infected men and WS (weight <90% IBW) | HIV-infected men and WS (weight <90% IBW) |
| Fairfield WP | 2001 | Testosterone         | 200 mg weekly    | 12 weeks           | Body composition                 | HIV-infected men with WS (weight <90% of IBW or weight loss >10% of baseline weight) | HIV-infected men with WS (weight <90% of IBW or weight loss >10% of baseline weight) |
| Storer TW  | 2005 | Nandrolone decanoate | 150 mg biweekly  | 12 weeks           | Body composition                 | HIV-associated weight loss (5–15% over 6 months) | HIV-associated weight loss (5–15% over 6 months) |
| Schrader S | 2005 | T                    | 5 g              | 4 weeks            | Te efficacy                      | HIV-hypogonadal               | HIV-hypogonadal               |
| Poretsky L | 2006 | DHEA                 | 100 mg to 400 mg orally daily | 8 weeks           | Endocrine and metabolic parameters | HIV-infected men with mild depression defined by 3≤x>5 criteria of DSM IV | HIV-infected men with mild depression defined by 3≤x>5 criteria of DSM IV |
| Grunfeld C | 2006 | Oxandrolone          | 20 or 40 or 80 mg orally daily | 12 weeks           | Body composition                 | HIV-infected men with WS syndrome (10%–20% weight loss or BMI <20 kg/m²) | HIV-infected men with WS syndrome (10%–20% weight loss or BMI <20 kg/m²) |
| Mulligan K | 2007 | Megestrol ± Testosterone | 800 mg daily ± 200 mg biweekly | 12 weeks           | Body composition                 | HIV-positive men with 5% or more weight loss or BMI <20 kg/m² | HIV-positive men with 5% or more weight loss or BMI <20 kg/m² |
| Sardar P   | 2010 | T and Nandrolone     | 250 and 150 mg biweekly | 12 weeks           | Testosterone vs Nandrolone       | HIV-infected men with WS       | HIV-infected men with WS       |

AIDS: acquired immunodeficiency syndrome; BMD: bone mineral density; BMI: body mass index; DHEA: dehydroepiandrosterone; DSM: diagnostic and statistical manual of mental disorders; ED: erectile dysfunction; HIV: human immunodeficiency virus; IBW: ideal body weight; QoL: quality of life; Te: testosterone; WS: wasting syndrome.

3.5. Efficacy—Testosterone Levels

Only 11 out of 17 trials reported changes in TT serum levels after treatment, for a total of 632 patients. Although the overall Te change was not significant after treatment (5.80 nmol/L: −0.53; 12.14, p = 0.070), as expected, a significant increase in Te was observed when Te was administered (11.61 nmol/L: 6.09; 17.12, p < 0.001) but was not observed when androgen-related molecules were used (−8.20 nmol/L: −18.00; 1.60, p = 0.010) (Supplementary Figure S3 Panel A). Sensitivity analyses confirmed this significant increase in both hypogonadal (11.47 nmol/L: 1.19; 21.75, p = 0.030) and not-hypogonadal men (13.20 nmol/L: 12.80; 13.60, p < 0.001) (Supplementary Figure S3 Panel B). Moreover, the Te administration significantly changed TT serum levels in men with WS (12.99 nmol/L: 7.37; 18.62, p < 0.001) (Supplementary Figure S3 Panel C).
Androgen administration did not globally influence fT serum levels (19.02 pmol/L: −3.54; 41.57, p = 0.100), although a significant increase was observed after the use of Te (16.11 pmol/L: 8.64; 23.58, p < 0.001) rather than androgen-related molecules (Supplementary Figure S4).

Changes in SHBG were reported in 11 studies, accounting for 343 patients. The administration of androgens significantly reduced the SHBG serum levels (p < 0.001) (Figure 4 Panel A). This reduction was confirmed after separately considering Te and other androgen-related molecules (Figure 4 Panel A). The difference in SHBG occurred at the limit of statistical significance in hypogonadal men (−13.26: −26.67; 0.15, p = 0.050), whereas only one study considered HIV-infected men without hypogonadism at baseline (Figure 4 Panel B). The reduction in SHBG serum levels was confirmed in men treated with WS (−15.92: −24.30; −7.54, p < 0.001), while only one study evaluated HIV-infected men without WS (Figure 4 Panel C).

| Study or Subgroup | Study group | Mean | SD | Total | Mean | SD | Total | Weight | Mean Difference IV, Random, 95% CI | Year |
|-------------------|-------------|------|----|-------|------|----|-------|--------|-----------------------------------|------|
| 1.11.1 Androgen-related molecules | Stratford 1999 | −6.5 | 2 | 27 | −6.7 | 3.4 | 27 | 14.6% | 0.20 [2.77, 3.33] | 1999 |
|                   | Storey 2005  | −7.9 | 4.5 | 43 | −6.6 | 3.1 | 22 | 15.0% | −0.30 [−1.17, −0.43] | 2005 |
|                   | Poreleau 2008 | −8   | 2.3 | 21 | 4   | 1.39 | 19 | 15.3% | −10.00 [−10.27, −9.73] | 2006 |
| Subtotal (95% CI) | 81           | 67   | 44.9% | 4.48 [−16.69, 1.73] |                |
| Heterogeneity: Total = 28.08; Ch² = 76.32, df = 2 (p < 0.00001); I² = 98% Test for overall effect Z = 4.14 (p = 0.001) |
| Total (95% CI)    | 175         | 168  | 100.0% | −9.12 [−14.19, −4.05] |                |
| Heterogeneity: Total = 43.58; Ch² = 233.11, df = 6 (p < 0.00001); I² = 97% Test for overall effect Z = 2.30 (p = 0.02) Test for subgroup differences: Ch² = 1.81, df = 1 (p = 0.16), I² = 44.7% |

Panel A

| Study or Subgroup | Study group | Mean | SD | Total | Mean | SD | Total | Weight | Mean Difference IV, Random, 95% CI | Year |
|-------------------|-------------|------|----|-------|------|----|-------|--------|-----------------------------------|------|
| 2.11.1 Men hypogonadal | Oommen 2008 | −11.8 | 9.6 | 24 | 0   | 9.3 | 26 | 24.6% | −11.80 [−17.05, −6.55] | 2000 |
| Subtotal (95% CI) | 24           | 26   | 24.6% | −11.80 [−17.05, −6.55] |                |
| Heterogeneity: Not applicable Test for overall effect Z = 4.41 (p = 0.0001) |

| Study or Subgroup | Study group | Mean | SD | Total | Mean | SD | Total | Weight | Mean Difference IV, Random, 95% CI | Year |
|-------------------|-------------|------|----|-------|------|----|-------|--------|-----------------------------------|------|
| 2.11.2 Hypogonadal | Oommen 1999 | −4.5 | 13.1 | 28 | 7.7 | 11.4 | 26 | 23.8% | −12.20 [−16.36, −8.03] | 1999 |
|                   | Brassi 1999 | 0.4  | 3.8 | 14 | 5.2 | 2.1 | 19 | 26.3% | −4.80 [−7.01, −2.59] | 1999 |
|                   | Knappe 2008 | −15.2 | 4.5 | 59 | 3.5 | 4.6 | 31 | 26.8% | −22.70 [−24.98, −20.43] | 2008 |
| Subtotal (95% CI) | 70           | 75   | 75.4% | −13.26 [−26.67, 0.15] |                |
| Heterogeneity: Total = 135.04; Ch² = 121.76, df = 2 (p < 0.00001); I² = 98% Test for overall effect Z = 2.34 (p = 0.02) |
| Total (95% CI)    | 94           | 101  | 100.0% | −12.90 [−23.49, −2.34] |                |
| Heterogeneity: Total = 111.52; Ch² = 122.11, df = 3 (p < 0.00001); I² = 98% Test for overall effect Z = 2.32 (p = 0.02) Test for subgroup differences: Ch² = 0.91, df = 1 (p = 0.34), I² = 0% |

Panel B

Figure 4. Cont.
Figure 4. Forest plot reporting groups detected in the second literature search for changes in sex hormone binding globulin (SHBG) between study and control groups (Panel A). Panel B reports the sensitivity analysis for hypogonadism, and Panel C shows the sensitivity analysis for wasting syndrome.

### 3.6. Body Composition

Body composition parameters were assessed by dual energy x-ray absorptiometry (12 studies) or by bioelectrical impedance analysis (five studies).

Body weight changes (WC) were reported in 12 studies, for a total of 734 patients. WC was lower when a placebo was administered instead of androgen therapy, although the difference did not reach a statistically significant level ($p = 0.060$) (Figure 5, Panel A). However, in 11 trials, Te was dispensed, whereas only one study used nandrolone (N). Considering only the action of Te, and comparing treated and untreated patients, the WC increase was significantly higher in the study group than in the control group ($p = 0.008$) (Figure 5, Panel A). Sensitivity analyses showed that body weight significantly changed when Te was administered in hypogonadal men ($1.27$ kg: $0.30$; $2.24$, $p = 0.010$), but not in eugonadal HIV-infected men ($0.59$ kg: $−0.66$; $1.85$, $p = 0.360$) (Supplementary Figure S5 Panel A). Considering the presence or absence of WS as an inclusion criterion, the administration of T significantly increased body weight in men with WS ($1.13$ kg: $0.39$; $1.86$, $p = 0.003$) (Supplementary Figure S5 Panel B), whereas only one study considered HIV-infected men without WS.
3.6. Body Composition

Body composition parameters were assessed by dual energy x-ray absorptiometry (12 studies) or by bioelectrical impedance analysis (five studies). Body weight changes (WC) were reported in 12 studies, for a total of 734 patients. WC was lower when a placebo was administered instead of androgen therapy, although the difference did not reach a statistically significant level ($p = 0.060$) (Figure 5, Panel A). However, in 11 trials, Te was dispensed, whereas only one study used Nandrolone (N). Considering only the action of Te, and comparing treated and untreated patients, the WC increase was significantly higher in the study group than in the control group ($p = 0.008$) (Figure 5, Panel A). Sensitivity analyses showed that body weight significantly changed when Te was administered in hypogonadal men (1.27 kg; 0.30; 2.24, $p = 0.010$), but not in eugonadal HIV-infected men (0.59 kg; −0.66; 1.85, $p = 0.360$) (Supplementary Figure S5 Panel A). Considering the presence or absence of WS as an inclusion criterion, the administration of T significantly increased body weight in men with WS (1.13 kg; 0.39; 1.86, $p = 0.003$) (Supplementary Figure S5 Panel B), whereas only one study considered HIV-infected men without WS.

The LBM change was reported in eight studies for a total of 447 patients and it was higher in the study group compared to the control group ($p < 0.001$) (Figure 5, Panel B). This androgen-mediated increase in LBM remains evident when also considering Te and N administration separately, although this effect seems to be more pronounced when using N instead of Te. Sensitivity analyses showed that the change in LBM was not significantly different when Te was administered in hypogonadal (0.97: −0.43; 2.36, $p = 0.170$) and not-hypogonadal men (1.70: −1.63; 5.04, $p = 0.320$) (Supplementary Figure S6 Panel A). Since only one study considered HIV-infected men without WS, the comprehensive evaluation of Te administration in WS patients revealed no significant changes in LBM (1.20: −0.59; 2.99, $p = 0.190$) (Supplementary Figure S6 Panel A). Thus, sensitivity analyses suggested that the androgen effect on LBM could not be predicted by hypogonadism or WS occurrence.

Changes in FFM were reported in six studies for a total of 251 patients, with higher results in the study group than in the control group ($p < 0.001$) (Figure 5, Panel C). This significant difference also remained when dividing studies between those using Te (four studies) and those using N (two studies) (Figure 5, Panel C). Sensitivity analyses were not performed.

Figure 5. Forest plot comparing study and control groups detected in the second literature search, considering body weight change (WC) (kg) (Panel A), lean body mass (LBM) (Panel B), and fat free mass (FFM) change (Panel C).
The LBM change was reported in eight studies for a total of 447 patients and it was higher in the study group compared to the control group \((p < 0.001)\) (Figure 5, Panel B). This androgen-mediated increase in LBM remains evident when also considering Te and N administration separately, although this effect seems to be more pronounced when using N instead of Te. Sensitivity analyses showed that the change in LBM was not significantly different when Te was administered in hypogonadal (0.97: −0.43; 2.36, \(p = 0.170\)) and not-hypogonadal men (1.70: −1.63; 5.04, \(p = 0.320\)) (Supplementary Figure S6 Panel A). Since only one study considered HIV-infected men without WS, the comprehensive evaluation of Te administration in WS patients revealed no significant changes in LBM (1.20: −0.59; 2.99, \(p = 0.190\)) (Supplementary Figure S6 Panel A). Thus, sensitivity analyses suggested that the androgen effect on LBM could not be predicted by hypogonadism or WS occurrence.

Changes in FFM were reported in six studies for a total of 251 patients, with higher results in the study group than in the control group \((p < 0.001)\) (Figure 5, Panel C). This significant difference also remained when dividing studies between those using Te (four studies) and those using N (two studies) (Figure 5, Panel C). Sensitivity analyses were not possible for evaluation of the presence of hypogonadism at baseline, since changes in FFM were not reported in studies evaluating not-hypogonadal men. Considering HIV-patients with or without WS at baseline, only one study evaluated men without WS and the remaining group of studies showed a significant change in FFM (2.82: 2.00; 3.63, \(p < 0.001\)). Similarly to LBM, these results suggest that changes in FFM could not be predicted by hypogonadism or WS at baseline.

Changes in fat mass (FM) were reported in nine studies, including a total of 537 patients. This change was not significantly different comparing treated and untreated HIV-positive men (0.03: −0.41; 0.47, \(p = 0.900\)) (Supplementary Figure S7 Panel A), independently of the androgenic compound used. However, sensitivity analyses showed that androgen administration significantly affected the FM in both hypogonadal \((p = 0.040)\) and not-hypogonadal men \((p = 0.020)\), although with opposite directions of causality (Supplementary Figure S7 Panel B). On the other hand, sensitivity analysis was not possible for the presence of WS, since no studies evaluating HIV-infected men without WS were available.

Changes in BMC were reported in five studies for a total of 475 patients. The administration of androgens did not change the BMC (0.47: −0.26; 1.20, \(p = 0.210\)), independently of the molecule used. Sensitivity analyses were not possible considering the low number of studies included in this subgroup analysis.

3.7. Safety

All studies included in the analysis reported the dropout rate. The odds ratio of the dropout rate did not significantly differ when comparing the study and control groups (Figure 6).
4. Discussion

Our systematic review and meta-analysis found that the prevalence of hypogonadism in HIV subjects is particularly high, especially when fT was considered. Accordingly, SHBG is increased and fT reduced in HIV subjects when compared to controls. In line with the latter results, a trend toward higher LH levels in HIV-infected men was observed, especially in older studies. Interventional analysis depicts a clear effect of androgen administration in HIV-infected men at increasing body weights, mainly due to a significant change in the lean body compartment.

The overall prevalence of hypogonadism in HIV-infected men was around 26% and up to 40% when fT was considered, confirming previous results [3]. Several narrative reviews attempted to describe the prevalence of hypogonadism in this group of patients, highlighting the high heterogeneity of the studies and, overall, of the methodologies used to measure and define male hypogonadism [3]. Present data show that the prevalence of hypogonadism in HIV subjects is similar to that reported in other subjects with chronic diseases [44], such as those with diabetes mellitus [45], metabolic syndrome (MetS) [46], or erectile dysfunction [47], or who are using drugs that potentially interfere with T production [48,49]. Conversely, HIV patients show from 10 to 20 times higher prevalence of hypogonadism when compared to the general population [50]. In addition, this meta-analysis confirms the results of a few studies showing that hypogonadism occurs earlier in HIV-infected men [4] when compared HIV-uninfected men since age was not associated with the occurrence of hypogonadism, as is generally expected in the general population [50]. A combination of genetic, environmental and age-related factors is supposed to
play the major role in determining the development of LOH [51,52]. The specific mechanisms underlying the development of hypogonadism in HIV patients are still largely unknown. Present data show similar TT serum levels between HIV-infected and uninfected men, when compared in the same setting. However, subjects with HIV showed higher SHBG and lower TT serum levels compared to healthy controls. In addition, no difference in gonadotropin levels was observed although a trend toward higher LH levels was found, suggesting the presence of mixed hypogonadism. It should be considered, however, that the trend for higher serum LH found in our meta-analysis refers mainly to studies performed in the 1990s (Figure 3 Panel D), including HIV patients who had survived the disease in the pre-HAART era; these patients were exposed to several opportunistic infections that, at the time, often also involved the testis, thus accounting for primary hypogonadism [53,54]. A large body of evidence has suggested that overall poor health status represents a major risk factor in HIV-related hypogonadism [5,8,12]. In line with the latter observation, we observed an inverse relationship between CD4+ cell count and the HIV-related prevalence of hypogonadism, suggesting that a worse HIV-infection control increases the risk of hypogonadism onset. Accordingly, hypogonadism was more frequently detected in the pre-ART area when opportunistic infections and overall poor health status were more frequently observed [3,12]. In line with the latter hypothesis, we reported an inverse relationship between HIV hypogonadism and the year of study publication. As was also the case for other HIV comorbidities, it seems that the prevalence of hypogonadism tended to decrease in recent years due to better control of HIV infection and the minor levels drug toxicity provided by newer antiretroviral drugs used alone or in combination [55]. Other factors that can negatively interfere with Te production in HIV patients include metabolic derangement as well as concomitant liver alterations with Hepatitis B Virus (HBV) or HCV co-infection, and the presence of inflammatory cytokines such as TNF-α and interleukin-1 [12]. Finally, ART per se, as well as the concomitant use of other drugs such as glucocorticoids, megestrol acetate, psychotropic medications and opiates or methadone, can all contribute to the development of hypogonadism in HIV populations [3,12].

When interventional studies were investigated, body weight modifications were limited to the use of T in hypogonadal men or HIV patients with WS. In addition, we found that body composition was changing, when considering either LBM or FFM, independently of the androgenic compound administered. Although these parameters are both expressions of the lean mass compartment and differ only in terms of the presence or absence of the essential fat, the administration of androgens seems not to exert a comparable effect. In particular, the action of androgens on LBM seems to not be influenced by baseline differences in terms of the presence of hypogonadism and/or WS. On the contrary, considering FFM, these baseline conditions seem to affect the action of androgens in HIV-infected men, which is modified in hypogonadal HIV subjects treated with Te, but not in eugonadal ones. The beneficial action of androgens on FFM is well known and was previously reported in other meta-analyses performed in HIV-uninfected men, in particular in middle-aged men [56], in patients with MetS [46] or in Klinefelter syndrome [57]. Although HIV patients present peculiar disease- and treatment-associated comorbidities, compared to the uninfected population, ageing males could be partially comparable, since they share some degree of metabolic alteration, including body composition changes. However, measuring the effect of chronic androgen administration on body composition remains challenging, as demonstrated by the lack of significant changes of BMC. Indeed, although the depletion of BMC represents one of the most appropriate criteria to identify the presence of WS [58], the evaluation of the effects of androgens on this outcome remains poor, probably due to the low number of studies reporting this parameter. Moreover, LBM, FFM and BMC could be measured by a significantly high number of diagnostic procedures, which could bias the final results due to heterogeneity. Thus, a single lean mass-related parameter and a specific diagnostic tool for this parameter remain far from being universally validated.
The action of androgens on the lean body compartment is independent of the molecule used, since changes are significant using both Te and N. However, only one study compared these two androgenic compounds in the same clinical setting [10], providing a direct comparison between the two arms and supporting a superior therapeutic effect of N in HIV-infected men with WS. These molecules differ in terms of the presence (Te) or the absence (N) of the methyl group in position C19, supplying N with enhanced anabolic effects and reduced androgenic properties [59]. Although the available data are not sufficient to highlight the predominance of a specific androgenic molecule in terms of the improvement of body composition parameters in HIV patients, it is important to emphasize that preliminary data suggest that oestrogens play a limited role on lean mass, which is mainly under the control of Te in men [60]. Moreover, the increasing use of N as a doping substance [61] has limited its clinical application, reducing the availability of data on this compound in the setting of HIV-infected patients.

Despite the demonstration of the efficacy of androgens in terms of body composition in HIV-infected men, the real mechanism through which this action is carried out remains unclear. Indeed, whether this beneficial change is mediated by the modification of serum Te levels is still debated. In the present meta-analysis, we could only evaluate an association between body changes and therapy, but not a cause-and-effect relationship. As expected, androgen administration increases TT serum levels only when Te is used instead of Te-analogues, independently of the gonadal baseline status. Accordingly, the same result is observed when considering fT levels. However, all androgen administrations reduced SHBG with a potential final increase in fT serum levels. Thus, despite these significant variations in serum hormonal levels, the biochemical mechanism by which Te affects body composition is not completely understood. The androgens’ capability to increase LBM, and consequently muscle mass, has been previously envisaged in different experimental settings [62,63]. In fact, Te is able to stimulate lipolysis in animal models [64], as well as in human subcutaneous adipose tissue, in which both a Te-induced inhibition of lipoprotein lipase and an activation of the hormone sensitive lipase were observed [65]. Physiological and supra-physiological Te levels were demonstrated to increase the number and the size of muscle fibres by stimulating protein synthesis [66]. The in vitro evaluation of the myoblasts’ culture system highlighted the capability of Te to induce muscle hypertrophy, as well as a non-genomic action, by activating a G-protein-linked receptor, which resulted in cellular growth [67]. With this in mind, it is not surprising that androgen treatment induces changes in muscle tissue, without detectable effects on adipose tissue, as confirmed by the absence of overall modifications in FM. However, a significant increase in FM was observed in hypogonadal Te-treated patients, while a significant decrease was observed in eugonadal HIV patients. The limited number of trials evaluating FM does not allow the obtaining of conclusive results, although we could speculate that the restoration of eugonadism in androgen-deficient patients could indirectly impact FM by improving general health status, mood and appetite. On the contrary, supra-physiological Te levels could act predominantly on the lean mass compartment, with a relative reduction in FM at equal body weight.

Sensitivity analyses show that the presence or absence of hypogonadism as well as of WS are not useful criteria for identifying patients who could benefit from androgenic treatment in terms of body composition. However, these subgroup analyses should be considered with caution, since the statistical power is reduced due to the limited number of included trials. Moreover, the vast majority of included studies evaluated patients with a history of WS or body weight reduction. These conditions, although typical of HIV infection, are heterogeneously defined [68], and this could be another relevant bias in the interpretation of sensitivity analyses.

Finally, all the results reported in the present meta-analysis should be cautiously evaluated, considering the high degree of heterogeneity among included studies. This variability is due to the absence of shared evidence-based parameters that are able to measure the lean body compartment, and to the high variability among studies in terms of the inclusion criteria, the mode of measurement of body composition, the androgenic
compounds selected, dosages, and scheme and route of administration. In addition, while only a few trials were designed to assess the lean mass compartment change in HIV settings, thus limiting data availability, the androgen therapeutic schemes were offered for a maximum of six months, making long-term considerations impossible. All these parameters should be considered, together with the low quality of the included studies, as depicted in the risk of bias evaluation, suggesting the high levels of difficulty involved in designing a clinical trial in HIV-infected patients.

In conclusion, our systematic review highlights an increased prevalence of hypogonadism in the young to middle-aged HIV-population compared to uninfected men. However, this comorbidity could remain neglected when only TT serum levels are measured. Interestingly, reduced Te serum levels reflect poor disease control, which was related to CD4+ cell count. In HIV-infected men, chronic androgen supplementations seem to exert a significant impact on body composition, particularly affecting the lean mass compartment. Indeed, the androgenic treatment for anabolic purposes in HIV male patients leads to a mild improvement of some body composition parameters, although this is not predictable. Moreover, since the vast majority of trials set up short-term treatment schemes, no data are currently available regarding the long-term effects of androgen administration in a HIV setting. Considering the general frailty of HIV patients and the significant burden of adverse effects that characterizes anabolic androgenic therapy, a personalized and tailored therapeutic approach is mandatory in such patients.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cells10082067/s1, Table S1: studies quality. Figure S1: Forest plot showing hypogonadism prevalence in studies detected in the first literature search, considering the overall group of studies included (Panel A) and excluding studies considering total testosterone serum levels above 12 nmol/L as hypogonadism cut off (Panel B). Figure S2: Meta-regression analysis comparing total testosterone serum levels and CD4+ cell count (Panel A) and year of publication (Panel B). Figure S3: Forest plot comparing study and control groups detected in the second literature search, for total testosterone change between study and control groups, reported as nmol/L (Panel A). Panel B reports sensitivity analysis for hypogonadism and Panel C sensitivity analysis for wasting syndrome. Figure S4: Forest plot comparing study and control groups detected in the second literature search, for free testosterone (fT) change between study and control groups, reported as pmol/L. Figure S5: Forest plot comparing study and control groups detected in the second literature search, considering body weight change (WC) (kg) in sensitivity analysis for hypogonadism (Panel A) and wasting syndrome (Panel B). Figure S6: Forest plot comparing study and control groups detected in the second literature search, considering lean body mass (LBM) in sensitivity analysis for hypogonadism (Panel A) and wasting syndrome (Panel B). Figure S7: Forest plot comparing study and control groups detected in the second literature search, for fat mass change between study and control groups (Panel A). Panel B reports sensitivity analysis for hypogonadism.

Author Contributions: D.S. conceived and designed the study, analysed and interpreted the data and drafted the article; G.S., W.V. and A.P. were involved in the acquisition of the data, the interpretation of the data and the drafting of the article; M.M. and V.R. critically revised the article for important intellectual content; G.C. conceived and designed the study, analysed and interpreted the data and drafted the article. All authors approved the final version of the manuscript for submission.

Funding: This study did not receive any funding.

Data Availability Statement: Data supporting reported results could be obtained after direct author request.

Acknowledgments: The authors have nothing to declare.

Conflicts of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References

1. Collaboration, A.T.C. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: A collaborative analysis of cohort studies. *Lancet HIV* 2017, 4, e349–e356. [CrossRef]

2. Srinivasa, S.; Grinspoon, S.K. Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients. *Eur. J. Endocrinol.* 2014, 170, R185–R202. [CrossRef]

3. Rochira, V.; Gueraud, G. Hypogonadism in the HIV-infected man. *Endocrinol. Metab. Clin. N. Am.* 2014, 43, 709–730. [CrossRef]

4. Rochira, V.; Zirilli, L.; Orlando, G.; Santi, D.; Brigante, G.; Dazzi, C.; Carli, F.; Carani, C.; Gueraud, G. Premature decline of serum total testosterone in HIV-infected men in the HAART-era. *PloS ONE* 2011, 6, e28512. [CrossRef] [PubMed]

5. De Vincentis, S.; Decaroli, M.C.; Fanelli, F.; Dazzi, C.; Mezzullo, M.; Morini, F.; Bertani, D.; Milic, J.; Carli, F.; Cuomo, G.; et al. Health status is related to testosterone, estrone and body fat: Moving to functional hypogonadism in men with HIV. *Eur. J. Endocrinol.* 2021, 184, 107–122. [CrossRef] [PubMed]

6. Corona, G.; Rastrelli, G.; Di Pasquale, G.; Sforza, A.; Mannucci, E.; Maggi, M. Endogenous Testosterone Levels and Cardiovascular Risk: Meta-Analysis of Observational Studies. *J. Sex. Med.* 2018, 15, 1260–1271. [CrossRef]

7. Corona, G.; Vignozzi, L.; Sforza, A.; Maggi, M. Risks and benefits of late onset hypogonadism treatment: An expert opinion. *World J. Men’s Health* 2013, 31, 103–125. [CrossRef]

8. Rochira, V.; Dazzi, C.; Santi, D.; Brigante, G.; Ansoloni, A.; Decaroli, M.C.; De Vincentis, S.; Stentarelli, C.; Zona, S.; Gueraud, G. Low testosterone is associated with poor health status in men with human immunodeficiency virus infection: A retrospective study. *Andrology* 2015, 3, 298–308. [CrossRef]

9. Tauchen, J.; Jurášek, M.; Huml, L.; Rimpelová, S. Medicinal Use of Testosterone and Related Steroids Revisited. *Molecules* 2021, 26, 1032. [CrossRef]

10. Sardar, P.; Jha, A.; Roy, D.; Majumdar, U.; Guha, P.; Roy, S.; Banerjee, R.; Banerjee, A.K.; Bandypadhyay, D. Therapeutic effects of nandrolone and testosterone in adult male HIV patients with AIDS wasting syndrome (AWS): A randomized, double-blind, placebo-controlled trial. *HIV Clin. Trials* 2010, 11, 220–229. [CrossRef]

11. Dudgeon, W.D.; Phillips, K.D.; Carson, J.A.; Brewer, R.B.; Durstine, J.L.; Hand, G.A. Counteracting muscle wasting in HIV-infected individuals. *HIV Med.* 2006, 7, 299–310. [CrossRef]

12. Mirza, F.S.; Luthra, P.; Chirch, L. Endocrinological aspects of HIV infection. *J. Endocrinol. Invest.* 2018, 41, 881–899. [CrossRef] [PubMed]

13. Jackson, A.S.; Pollock, M.L. Practical Assessment of Body Composition. *Physician Sportsmed.* 1985, 13, 76–90. [CrossRef]

14. Mynarcik, D.C.; McNurlan, M.A.; Steigbigel, R.T.; Fuhrer, J.; Gelato, M.C. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. *J. Acquir. Immune Defic. Syndr. 2000*, 25, 312–321. [CrossRef]

15. Vigouroux, C.; Maachi, M.; Nguyen, T.H.; Coussieu, C.; Gharakhanian, S.; Funahashi, T.; Matsuzaawa, Y.; Shimomura, I.; Rozenbaum, W.; Capeau, J.; et al. Serum adipokytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. *AIDS 2003*, 17, 1503–1511. [CrossRef]

16. Wohl, D.; Scherzer, R.; Heymsfield, S.; Simberkoff, M.; Sidney, S.; Bacchetti, P.; Grunfeld, C. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. *J. Acquir. Immune Defic. Syndr. 2008*, 48, 44–52. [CrossRef]

17. Chlebowski, R.T.; Grosvener, M.B.; Bernhard, N.H.; Morales, L.S.; Bulcavage, L.M. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. *Am. J. Gastroenterol.* 1989, 84, 1288–1293.

18. Kotler, D.P.; Tierney, A.R.; Wang, J.; Pierson, R.N., Jr. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. *Am. J. Clin. Nutr.* 1989, 50, 444–447. [PubMed]

19. Kashkin, K.B.; Kleber, H.D. Hooked on hormones? An anabolic steroid addiction hypothesis. *JAMA* 1989, 262, 3166–3170. [CrossRef]

20. Johns, K.; Beddall, M.J.; Corrin, R.C. Anabolic steroids for the treatment of weight loss in HIV-infected individuals. *Cochrane Database Syst. Rev.* 2005, CD005483. [CrossRef]

21. Fairfield, W.P.; Treat, M.; Rosenthal, D.I.; Frontera, W.; Stanley, T.; Corcoran, C.; Costello, M.; Parlin, K.; Schoenfeld, D.; Kibanski, A.; et al. Effects of testosterone and exercise on muscle leanness in eugonadal men with AIDS wasting syndrome (AWS): A randomized, double-blind, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting. *J. Appl. Physiol.* 2000, 90, 2166–2171. [PubMed]

22. Hengge, U. HIV and testosterone therapy. *Lancet. Infect. Dis.* 2003, 3, 187–188. [CrossRef]

23. Hengge, U.R. Testosterone replacement for hypogonadism: Clinical findings and best practices. *AIDS Read.* 2003, 13, S15–S21. [PubMed]

24. Hengge, U.R.; Stocks, K.; Wiehler, H.; Faulkner, S.; Esser, S.; Lorenz, C.; Jentzen, W.; Hengge, D.; Goos, M.; Dudley, R.E.; et al. Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting. *Aids* 2003, 17, 699–710. [CrossRef]

25. Rabkin, J.G.; Wagner, G.J.; McElhiney, M.C.; Rabkin, R.; Lin, S.H. Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: A placebo-controlled trial. *J. Clin. Psychopharmacol.* 2004, 24, 379–385. [CrossRef]

26. Choi, H.H.; Gray, P.B.; Storer, T.W.; Calof, O.M.; Woodhouse, L.; Singh, A.B.; Padero, C.; Mac, R.P.; Sinha-Hikim, I.; Shen, R.; et al. Effects of testosterone replacement in human immunodeficiency virus-infected women with weight loss. *J. Clin. Endocrinol. Metab.* 2005, 90, 1531–1541. [CrossRef]
27. Corona, G.; Rastrelli, G.; Maggi, M. Diagnosis and treatment of late-onset hypogonadism: Systematic review and meta-analysis of TRT outcomes. Best Pract. Res. Clin. Endocrinol. Metab. 2013, 27, 557–579. [CrossRef]

28. Santi, D.; Corona, G. Primary and secondary hypogonadism. In Endocrinol of the Testis and Male Reprod; Simoni, M., Huhtaniemi, I., Lenzi, A., Jannini, E.A., Eds.; Endocrinology; Springer: Cham, Switzerland, 2017.

29. Bhasin, S.; Basaria, S. Diagnosis and treatment of hypogonadism in men. Best Pract. Res. Clin. Endocrinol. Metab. 2011, 25, 251–270. [CrossRef]

30. Rastrelli, G.; Guaraldi, F.; Reismann, Y.; Sforza, A.; Isidori, A.M.; Maggi, M.; Corona, G. Testosterone Replacement Therapy for Sexual Symptoms. Sex. Med. Rev. 2019, 7, 464–475. [CrossRef]

31. Bhasin, S.; Rastrelli, T.W.; Asbel-Sethi, N.; Kilbourne, A.; Hays, R.; Sinha-Hikim, I.; Shen, R.; Arver, S.; Beall, G. Effects of testosterone replacement with a nongential, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J. Clin. Endocrinol. Metab. 1998, 83, 3155–3162. [CrossRef]

32. Bhasin, S.; Rastrelli, T.W.; Javanbakht, M.; Berman, N.; Yarasheski, K.E.; Phillips, J.; Dike, M.; Sinha-Hikim, I.; Shen, R.; Hays, R.D.; et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 2000, 283, 763–770. [CrossRef]

33. Dobs, A.S.; Cofrancesco, J.; Nolten, W.E.; Danoff, A.; Anderson, R.; Hamilton, C.D.; Feinberg, J.; Seekins, D.; Yangco, B.; Khane, F. The use of a transcutaneous testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. Am. J. Med. 1999, 107, 126–132. [CrossRef]

34. Grinspoon, S.; Corcoran, C.; Askari, H.; Schoenfeld, D.; Wolf, L.; Burrows, B.; Walsh, M.; Hayden, D.; Perlman, K.; Anderson, E.; et al. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1998, 129, 18–26. [CrossRef]

35. Grinspoon, S.; Corcoran, C.; Stanley, T.; Katznelson, L.; Klambanski, A. Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting. J. Clin. Endocrinol. Metab. 1998, 83, 4251–4256. [CrossRef] [PubMed]

36. Knapp, P.E.; Storer, T.W.; Herbst, K.L.; Singh, A.B.; Dzekov, C.; Dzekov, J.; LaValley, M.; Zhang, A.; Ulloor, J.; Bhasin, S. Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss. Am. J. Physiol. Endocrinol. Metab. 2008, 294, E1135–E1143. [CrossRef]

37. Schrader, S.; Mills, A.; Scherperle, M.; Block, J.E. Improvement in sexual functioning and satisfaction in nonresponders to testosterone gel: Clinical effectiveness in hypogonadal, HIV-positive males. Clin. Cornerstone 2005, 7 (Suppl. 4), S26–S31. [CrossRef]

38. Rabkin, J.G.; Wagner, G.J.; Rabkin, R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch. Gen. Psychiatry 2000, 57, 141–147; discussion 155–146. [CrossRef]

39. Coodley, G.O.; Coodley, M.K. A trial of testosterone therapy for HIV-associated weight loss. AIDS 1997, 11, 1347–1352. [CrossRef]

40. Grinspoon, S.; Corcoran, C.; Perlman, K.; Costello, M.; Rosenthal, D.; Anderson, E.; Stanley, T.; Schoenfeld, D.; Burrows, B.; Hayden, D.; et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann. Intern. Med. 2000, 133, 348–355. [CrossRef]

41. Grinspoon, S.; Corcoran, C.; Stanley, T.; Baaj, A.; Basgoz, N.; Klambanski, A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J. Clin. Endocrinol. Metab. 2000, 85, 60–65. [CrossRef]

42. Grunfeld, C.; Kotler, D.P.; Dobs, A.; Glesby, M.; Bhasin, S. Oxandrolone in the treatment of HIV-associated weight loss in men: A randomized, double-blind, placebo-controlled study. J. Acquir. Immune Defic. Syndr. 2006, 41, 304–314. [CrossRef]

43. Mulligan, T.; Iranmanesh, A.; Veldhuis, J.D. Pulsatile iv infusion of recombinant human LH in leuprolide-suppressed patients unmasks impoverished Leydig-cell secretory responsiveness to midphysiological LH drive in the aging male. J. Clin. Endocrinol. Metab. 2001, 86, 5547–5553. [CrossRef]

44. Rochira, V. Hypogonadism in Systemic Diseases. In Endocrinol of the Testis and Male Reproduction; Simoni, M., Huhtaniemi, I.T., Eds.; Springer International Publishing: Cham, Switzerland, 2017; pp. 829–879.

45. Corona, G.; Rastrelli, G.; Marchiani, S.; Filippi, S.; Morelli, A.; Sarchielli, E.; Sforza, A.; Vignozzi, L.; Maggi, M. The Role of testosterone treatment in patients with metabolic disorders. Expert Rev. Clin. Pharmac. 2021, 1–13. [CrossRef]

46. Maserefe, E.; Corona, G.; Rastrelli, G.; Lotti, F.; Cipriani, S.; Forti, G.; Mannucci, E.; Maggi, M. Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: A comparative study. J. Sex. Med. 2015, 12, 956–965. [CrossRef]

47. Coluzzi, F.; Billeci, D.; Maggi, M.; Corona, G. Testosterone deficiency in non-cancer opioid-treated patients. J. Endocrinol. Investig. 2018, 41, 1377–1388. [CrossRef]

48. Corona, G.; Rastrelli, G.; Marchiani, S.; Filippi, S.; Morelli, A.; Sarchielli, E.; Sforza, A.; Vignozzi, L.; Maggi, M. Consequences of Anabolic-Androgenic Steroid Abuse in Males; Sexual and Reproductive Perspective. World J. Men’s Health 2021, 39. [CrossRef]

49. Wu, F.C.; Tajar, A.; Beynon, J.M.; Pye, S.R.; Silman, A.J.; Finn, J.D.; O’Neill, T.W.; Bartfai, G.; Casanueva, F.F.; Forti, G.; et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N. Engl. J. Med. 2010, 363, 123–135. [CrossRef]

50. Cangiano, B.; Duminuco, P.; Vezzoli, V.; Guizzardi, F.; Chiiodini, I.; Corona, G.; Maggi, M.; Persani, L.; Bonomi, M. Evidence for a Common Genetic Origin of Classic and Milder Adult-Onset Forms of Isolated Hypogonadotropic Hypogonadism. J. Clin. Med. 2019, 8, 126. [CrossRef]
52. Nieschlag, E. Late-onset hypogonadism: A concept comes of age. *Andrology* **2020**, *8*, 1506–1511. [CrossRef]
53. Maggi, M.; Forti, G. Gonadal function in AIDS. *Bailliere’s Clin. Endocrinol. Metab.* **1994**, *8*, 849–857. [CrossRef]
54. Dobs, A.S.; Few, W.L., 3rd; Blackman, M.R.; Harman, S.M.; Hoover, D.R.; Graham, N.M. Serum hormones in men with human immunodeficiency virus-associated wasting. *J. Clin. Endocrinol. Metab.* **1996**, *81*, 4108–4112. [CrossRef]
55. Ghosn, J.; Taiwo, B.; Seedat, S.; Autrana, B.; Katlama, C. HIV. *Lancet* **2018**, *392*, 685–697. [CrossRef]
56. Isidori, A.M.; Giannetta, E.; Greco, E.A.; Gianfrilli, D.; Bonifacio, V.; Isidori, A.; Lenzi, A.; Fabbri, A. Effects of testosterone on bone metabolism, serum lipid profile in middle-aged men: A meta-analysis. *Clin. Endocrinol.* **2005**, *63*, 280–293. [CrossRef]
57. Pizzocaro, A.; Vena, W.; Condorelli, R.; Radicioni, A.; Rastrelli, G.; Pasquali, D.; Selice, R.; Ferlin, A.; Foresta, C.; Jannini, E.A.; et al. Testosterone treatment in male patients with Klinefelter syndrome: A systematic review and meta-analysis. *J. Endocrinol. Investig.* **2020**, *43*, 1675–1687. [CrossRef]
58. Polsky, B.; Kotler, D.; Steinhardt, C. Treatment guidelines for HIV-associated wasting. *HIV Clin. Trials* **2004**, *5*, 50–61. [CrossRef]
59. Pomara, C.; Barone, R.; Marino Gammazza, A.; Sangiorgi, C.; Barone, F.; Pitruzzella, A.; Locorotondo, N.; Di Gaudio, F.; Salerno, M.; Maglietta, F.; et al. Effects of Nandrolone Stimulation on Testosterone Biosynthesis in Leydig Cells. *J. Cell Physiol.* **2016**, *231*, 1385–1391. [CrossRef]
60. Finkelstein, J.S.; Lee, H.; Burnett-Bowie, S.A.; Pallais, J.C.; Yu, E.W.; Borges, L.F.; Jones, B.F.; Barry, C.V.; Wulczyn, K.E.; Thomas, B.J.; et al. Gonadal steroids and body composition, strength, and sexual function in men. *N. Engl. J. Med.* **2013**, *369*, 1011–1022. [CrossRef]
61. Nieschlag, E.; Vorona, E. Doping with anabolic androgenic steroids (AAS): Adverse effects on non-reproductive organs and functions. *Rev. Endocr. Metab. Disord.* **2015**, *16*, 199–211. [CrossRef]
62. Jensen, R.C.; Christensen, L.L.; Nielsen, J.; Schroder, H.D.; Kvorning, T.; Gejl, K.; Hojlund, K.; Glintborg, D.; Andersen, M. Mitochondria, glycogen, and lipid droplets in skeletal muscle during testosterone treatment and strength training: A randomized, double-blinded, placebo-controlled trial. *Andrology* **2018**, *6*, 547–555. [CrossRef]
63. Magnussen, L.V.; Hvid, L.G.; Hermann, A.P.; Hougaard, D.M.; Gram, B.; Caserotti, P.; Andersen, M.S. Testosterone therapy preserves muscle strength and power in aging men with type 2 diabetes-a randomized controlled trial. *Andrology* **2017**, *5*, 946–953. [CrossRef] [PubMed]
64. Maneschi, E.; Morelli, A.; Filippi, S.; Cellai, I.; Comeglio, P.; Mazzanti, B.; Mello, T.; Calcagno, A.; Sarchielli, E.; Vignozzi, L.; et al. Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements. *J. Endocrinol.* **2012**, *215*, 347–362. [CrossRef] [PubMed]
65. Frederiksen, L.; Hojlund, K.; Hougaard, D.M.; Mosbech, T.H.; Larsen, R.; Flyvbjerg, A.; Frystyk, J.; Brixen, K.; Andersen, M. Testosterone therapy decreases subcutaneous fat and adiponectin in aging men. *Eur. J. Endocrinol.* **2012**, *166*, 469–476. [CrossRef] [PubMed]
66. Ferrando, A.A.; Tipton, K.D.; Doyle, D.; Phillips, S.M.; Cortiella, J.; Wolfe, R.R. Testosterone injection stimulates net protein synthesis but not tissue amino acid transport. *Am. J. Physiol.* **1998**, *275*, E864–E871. [CrossRef]
67. Estrada, M.; Espinosa, A.; Muller, M.; Jaimovich, E. Testosterone stimulates intracellular calcium release and mitogen-activated protein kinases via a G protein-coupled receptor in skeletal muscle cells. *Endocrinology* **2003**, *144*, 3586–3597. [CrossRef]
68. Mankal, P.K.; Kotler, D.P. From wasting to obesity, changes in nutritional concerns in HIV/AIDS. *Endocrinol. Metab. Clin.* **2014**, *43*, 647–663. [CrossRef] [PubMed]